

BEAT-CORONA: Building evidence to advance treatments for COVID-19

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
22/04/2020	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
15/07/2020	Completed	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
21/07/2020	Infections and Infestations	<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.

In 2020, the virus has spread to many countries around the world and neither a vaccine against the virus or specific treatment for COVID-19 has yet been developed. As of March 2020, it is advised that people minimize travel and social contact, and regularly wash their hands to reduce the spread of the virus.

Groups who are at a higher risk from infection with the virus, and therefore of developing COVID-19, include people aged over 70 years, people who have long-term health conditions (such as asthma or diabetes), people who have a weakened immune system and people who are pregnant. People in these groups, and people who might come into contact with them, can reduce this risk by following the up-to-date advice to reduce the spread of the virus.

BEAT-CORONA is a research study that will look at what makes COVID-19 infection more likely or more severe in some individuals, so we can understand how the disease spreads, and its impact on patients and the NHS. It will also help to support studies testing treatments that may prevent or cure COVID-19. In particular, it is focused on vulnerable populations such as kidney patients, vasculitis patients and inflammatory bowel disease patients and healthcare workers who are uniquely exposed to COVID-19 through occupational activities undertaken in diagnosing and treating patients. This study will conduct real-time monitoring of the impact of the outbreak on these groups of people using a smartphone application or the study website. Information will be collected including demographics and clinical data. Findings from this study will help to understand how different people are affected by COVID-19.

Who can participate?

Persons at risk of COVID-19.

What does the study involve?

Participants will be asked to submit information using the study smartphone application at baseline and periodically for as long as the study continues. Notifications and questionnaires will be sent to participants via in-app push notifications.

What are the possible benefits and risks of participating?

The benefits are that they will be contributing to the fight against COVID19 by helping doctors and the NHS to understand how people are affected by COVID19. As this is an observational study there are no risks associated with participation.

Where is the study run from?

Addenbrookes Hospital (UK)

When is the study starting and how long is it expected to run for?

May 2020 to April 2025

Who is funding the study?

Cambridge Biomedical Research Centre (UK)

Who is the main contact?

Unfortunately, this study is not recruiting public volunteers at this time. This is because the research isn't ready for volunteers yet or the researchers are directly identifying volunteers in certain areas or hospitals. Please do not contact the research team as they will not be able to respond. For more information about COVID-19 research, visit the [Be Part of Research](#) homepage.

Contact information

Type(s)

Public

Contact name

Dr Kerrie Brusby

Contact details

Cambridge Clinical Trials Unit

Box 401

Cambridge University Hospitals NHS Foundation Trust

Addenbrooke's Hospital

Level 6

Coton House

Hills Road

Cambridge

United Kingdom

CB2 0QQ

+44 (0)1223 254472

add-tr.beat-corona@nhs.net

Type(s)

Scientific

Contact name

Dr Thomas F Hiemstra

ORCID ID

<https://orcid.org/0000-0002-2115-8689>

Contact details

Cambridge Clinical Trials Unit

Box 40

Addenbrookes Hospital

Hills Road

Cambridge

United Kingdom

CB2 0QQ

+44 (0)1223 336817

tfh24@cam.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2020-002016-48

Integrated Research Application System (IRAS)

282317

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CTU0306, IRAS 282317

Study information

Scientific Title

Building Evidence to Advance Treatments - COnprehensive COhort NAtional COVID-19 Study (BEAT-CORONA)

Acronym

BEAT-CORONA

Study objectives

The rationale of the study is to understand the epidemiology of COVID-19 infection in vulnerable groups (patients with kidney disease, vasculitis and related auto-immune disorders, inflammatory bowel disease and in the healthcare workforce) and its effect on clinical outcomes and the healthcare service.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Prospective observational comprehensive cohort study

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

Interventions

Participants will be asked to submit information using the study smartphone application at baseline and periodically for as long as the study continues. Notifications and questionnaires will be sent to participants via in-app push notifications. Baseline data collected will include: baseline demographic data, baseline clinical data (comorbidities, medication, COVID-19 status and symptoms), smoking history and work environment (HCW only). Weekly follow-up data will include COVID-19 status.

Intervention Type

Other

Primary outcome(s)

COVID-19 status, weekly during pandemic, via smartphone questionnaire

Key secondary outcome(s)

1. Risk factors for COVID-19 infection, weekly during pandemic, via smartphone questionnaire
2. Prognostic factors for clinical outcomes after COVID-19 infection, weekly during pandemic, via smartphone questionnaire

Completion date

30/04/2025

Eligibility

Key inclusion criteria

At risk of COVID-19

Participant type(s)

Mixed

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Unable to provide informed consent

Date of first enrolment

24/08/2020

Date of final enrolment

01/05/2024

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Addenbrookes Hospital

Cambridge University Hospitals NHS Foundation Trust

Hills Road

Cambridge

United Kingdom

CB2 0QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust

ROR

<https://ror.org/04v54gj93>

Organisation

University of Cambridge

ROR

<https://ror.org/013meh722>

Funder(s)

Funder type

University/education

Funder Name

Cambridge Biomedical Research Centre

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes